Clinical Research Directory
Browse clinical research sites, groups, and studies.
SGLT2i, Pioglitazone, and Ketone Production in T2D
Sponsor: The University of Texas Health Science Center at San Antonio
Summary
To examine whether the empagliflozin-induced stimulation of EGP, lipolysis, and ketone production in T2D individuals can be blocked by pioglitazone (which has direct hepatic and adipose tissue effects).
Official title: Protocol lV: SGLT2 Inhibitors, Pioglitazone and Ketone Production in Type 2 Diabetes Mellitus
Key Details
Gender
All
Age Range
30 Years - 75 Years
Study Type
INTERVENTIONAL
Enrollment
64
Start Date
2026-07-20
Completion Date
2027-06-30
Last Updated
2026-03-13
Healthy Volunteers
No
Conditions
Interventions
Empagliflozin 25 MG plus Pioglitazone placebo
A medication used in the management and treatment of type 2 diabetes mellitus. It is in the sodium-glucose co-transporter (SGLT-2) class of medications.
Pioglitazone 15 mg increased to 30 mg after 2 weeks plus Empagliflozin Placebo
Placebo-Inert tablet
Empagliflozin 25 mg/d plus Pioglitazone (15/30 mg/d)
Pioglitazone, a medication used in the management and treatment of type 2 diabetes mellitus. It is in the thiazolidinedione class of medications
Pioglitazone placebo + Empagliflozin placebo
Placebo-Inert tablet
Locations (1)
Texas Diabetes Institute/UH
San Antonio, Texas, United States